Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Myeloproliferative neoplasms (MPNs) are clonal myeloid malignancies associated with reduced life expectancy due to thrombosis, fibrosis, leukemic transformation, and infections.
• The Janus kinase 2 (JAK2) V617F mutation is a primary driver in BCR-ABL1-negative MPNs, activating the JAK-STAT signaling pathway.
• JAK inhibitors represent a therapeutic strategy by targeting this aberrant signaling pathway.

Purpose of the Study:

• To review the impact of JAK inhibitors on immune cells in MPN patients.
• To elucidate the clinical consequences of JAK inhibitor-induced immune modulation, focusing on infectious complications.

Main Methods:

• Literature review of studies on JAK inhibitors in MPNs.
• Analysis of the effects of JAK inhibitors on innate and adaptive immune cells.
• Evaluation of clinical data regarding adverse events and infectious complications.

Main Results:

• JAK inhibitors, such as ruxolitinib, effectively manage MPN symptoms and improve quality of life.
• These drugs interfere with JAK-STAT signaling, impacting various immune cells including dendritic cells, NK cells, T helper cells, and regulatory T cells.
• Impairment of immune function due to JAK inhibitors can lead to immune suppression and increased susceptibility to infections.

Conclusions:

• While JAK inhibitors offer significant clinical benefits for MPN patients, their immunomodulatory effects necessitate careful monitoring.
• Understanding the impact on immune cells is crucial for managing adverse events, particularly infectious complications.
• Further research is needed to optimize JAK inhibitor therapy and mitigate immunosuppression risks in MPN management.